Brief: Atossa Therapeutics Says Received Non-Compliance Letter From Nasdaq
07/10/2022 22:31
Oct 7 (Reuters) - Atossa Therapeutics Inc ATOS.O :
* ATOSSA THERAPEUTICS- ON OCT 5, CO RECEIVED LETTER FROM
NASDAQ
THAT COMPANY WAS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE
5550(A)(2)
Further company coverage: ATOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary